PL366000A1 - Konstrukty kwasu nukleinowego, transformowane przez nie komórki naczyniowe oraz kompozycje farmaceutyczne i sposoby, wykorzystujące je do indukowaniarozwoju naczyń - Google Patents
Konstrukty kwasu nukleinowego, transformowane przez nie komórki naczyniowe oraz kompozycje farmaceutyczne i sposoby, wykorzystujące je do indukowaniarozwoju naczyńInfo
- Publication number
- PL366000A1 PL366000A1 PL01366000A PL36600001A PL366000A1 PL 366000 A1 PL366000 A1 PL 366000A1 PL 01366000 A PL01366000 A PL 01366000A PL 36600001 A PL36600001 A PL 36600001A PL 366000 A1 PL366000 A1 PL 366000A1
- Authority
- PL
- Poland
- Prior art keywords
- nucleic acid
- pharmaceutical compositions
- cells transformed
- acid constructs
- methods utilizing
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000033115 angiogenesis Effects 0.000 title 1
- 230000001939 inductive effect Effects 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 title 1
- 210000005167 vascular cell Anatomy 0.000 title 1
- 102000009088 Angiopoietin-1 Human genes 0.000 abstract 2
- 108010048154 Angiopoietin-1 Proteins 0.000 abstract 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0045—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent agent being a peptide or protein used for imaging or diagnosis in vivo
- A61K49/0047—Green fluorescent protein [GFP]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/49—Platelet-derived growth factor [PDGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
- C12N2840/206—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES having multiple IRES
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Radiology & Medical Imaging (AREA)
- Physics & Mathematics (AREA)
- Heart & Thoracic Surgery (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22372700P | 2000-08-08 | 2000-08-08 | |
| PCT/IL2001/000733 WO2002012539A2 (en) | 2000-08-08 | 2001-08-08 | Nucleic acid constructs, vascular cells transformed therewith, pharmaceutical compositions and methods utilizing same for inducing angiogenesis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL366000A1 true PL366000A1 (pl) | 2005-01-24 |
Family
ID=22837748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL01366000A PL366000A1 (pl) | 2000-08-08 | 2001-08-08 | Konstrukty kwasu nukleinowego, transformowane przez nie komórki naczyniowe oraz kompozycje farmaceutyczne i sposoby, wykorzystujące je do indukowaniarozwoju naczyń |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7767201B2 (pl) |
| EP (2) | EP1307582B1 (pl) |
| JP (1) | JP2004520009A (pl) |
| AT (1) | ATE397087T1 (pl) |
| AU (1) | AU2001280060A1 (pl) |
| CA (1) | CA2418936A1 (pl) |
| CZ (1) | CZ2003444A3 (pl) |
| DE (1) | DE60134234D1 (pl) |
| HU (1) | HUP0300727A3 (pl) |
| IL (1) | IL154324A0 (pl) |
| PL (1) | PL366000A1 (pl) |
| WO (1) | WO2002012539A2 (pl) |
| ZA (1) | ZA200301386B (pl) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7387645B2 (en) * | 2003-04-25 | 2008-06-17 | Medtronic Vascular, Inc. | Cellular therapy to heal vascular tissue |
| US20090304650A1 (en) * | 2005-05-11 | 2009-12-10 | Scott Edward W | Repair of the Bone Marrow Vasculature |
| US20070123486A1 (en) * | 2005-11-15 | 2007-05-31 | Andrea Banfi | Composition for coordinated VEGF and PDGF expression, and methods of use |
| JP5121155B2 (ja) * | 2006-03-14 | 2013-01-16 | 独立行政法人物質・材料研究機構 | 形質転換細胞集団の作成方法 |
| US9598673B2 (en) * | 2006-05-19 | 2017-03-21 | Creative Medical Health | Treatment of disc degenerative disease |
| US7943590B2 (en) * | 2007-03-16 | 2011-05-17 | Multi-Gene Vascular Systems Ltd. | Compositions and methods for treating ophthalmic disorders |
| CN102242148A (zh) * | 2010-10-09 | 2011-11-16 | 苏州大学 | 重组载体以及转基因骨髓基质细胞修饰的丝素膜及其应用 |
| ES2651716T3 (es) * | 2012-11-02 | 2018-01-29 | Cornell University | Acondicionamiento angiogénico para potenciar la reprogramación celular cardiaca de fibroblastos del miocardio infartado |
| CN114457003A (zh) * | 2020-11-10 | 2022-05-10 | 维思尔治疗有限公司 | 预调节血管细胞用于转导的方法、转导方法和保存转导的细胞的方法 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4900556A (en) * | 1985-04-26 | 1990-02-13 | Massachusetts Institute Of Technology | System for delayed and pulsed release of biologically active substances |
| US5674722A (en) | 1987-12-11 | 1997-10-07 | Somatix Therapy Corporation | Genetic modification of endothelial cells |
| US6001350A (en) | 1987-12-11 | 1999-12-14 | Somatix Therapy Corp | Genetic modification of endothelial cells |
| US4950483A (en) * | 1988-06-30 | 1990-08-21 | Collagen Corporation | Collagen wound healing matrices and process for their production |
| US5219739A (en) * | 1989-07-27 | 1993-06-15 | Scios Nova Inc. | DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121 |
| US5980885A (en) * | 1991-07-08 | 1999-11-09 | Neurospheres Holdings Ltd. | Growth factor-induced proliferation of neural precursor cells in vivo |
| CA2117893A1 (en) * | 1992-05-18 | 1993-11-25 | Paul J. Godowski | Variant dimers for receptor activation |
| US5618544A (en) * | 1992-08-12 | 1997-04-08 | Bays-Brown Dermatologics, Inc. | Method of decreasing cutaneous senescence |
| DE4228457A1 (de) * | 1992-08-27 | 1994-04-28 | Beiersdorf Ag | Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen |
| US6007987A (en) | 1993-08-23 | 1999-12-28 | The Trustees Of Boston University | Positional sequencing by hybridization |
| US5962427A (en) * | 1994-02-18 | 1999-10-05 | The Regent Of The University Of Michigan | In vivo gene transfer methods for wound healing |
| US5821919A (en) * | 1994-04-29 | 1998-10-13 | Intel Corporation | Apparatus for table-driven conversion of pixels from YVU to RGB format |
| US6090618A (en) * | 1996-10-07 | 2000-07-18 | Arch Development Corporation | DNA constructs and viral vectors comprising a smooth muscle promoter |
| US5641750A (en) * | 1995-11-29 | 1997-06-24 | Amgen Inc. | Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product |
| JP2000502682A (ja) | 1995-12-22 | 2000-03-07 | ローカルメッド インコーポレイテッド | 血管新生を促進する成長因子の局所的血管内デリバリー |
| US5785965A (en) * | 1996-05-15 | 1998-07-28 | The Board Of Trustees Of The Leland Stanford Junior Univ. | VEGF gene transfer into endothelial cells for vascular prosthesis |
| JP2001503978A (ja) * | 1996-10-23 | 2001-03-27 | ウエイク・フオレスト・ユニバーシテイ | 標的化された細胞障害性細胞 |
| FI970784A7 (fi) * | 1997-02-25 | 1998-08-26 | Nokia Corp | Prosessien välinen vuonvalvonta hajautetussa moniprosessoriympäristössä |
| US6099832A (en) * | 1997-05-28 | 2000-08-08 | Genzyme Corporation | Transplants for myocardial scars |
| CA2225185A1 (en) * | 1997-08-11 | 1999-02-11 | Peter K. Law | Myoblast transfer therapy for relieving pain and for treating behavioral and perceptive abnormalities |
| CA2266805C (en) * | 1998-03-27 | 2015-04-28 | An-Go-Gen Inc. | Cell-based gene therapy in the treatment of pulmonary disorders |
| US6206914B1 (en) * | 1998-04-30 | 2001-03-27 | Medtronic, Inc. | Implantable system with drug-eluting cells for on-demand local drug delivery |
| CA2354846A1 (en) * | 1998-12-23 | 2000-06-29 | Regeneron Pharmaceuticals, Inc. | Method of enhancing the biological activity of ligands |
| EP1016726A1 (en) * | 1998-12-30 | 2000-07-05 | Introgene B.V. | Gene therapy to promote angiogenesis |
| US6328762B1 (en) * | 1999-04-27 | 2001-12-11 | Sulzer Biologics, Inc. | Prosthetic grafts |
| US6554857B1 (en) * | 1999-07-20 | 2003-04-29 | Medtronic, Inc | Transmural concentric multilayer ingrowth matrix within well-defined porosity |
| WO2002022176A1 (en) | 2000-09-15 | 2002-03-21 | Genvec, Inc. | Method of modulating neovascularization |
| US20030027751A1 (en) * | 2001-04-10 | 2003-02-06 | Genvec, Inc. | VEGF fusion proteins |
-
2001
- 2001-08-08 JP JP2002517823A patent/JP2004520009A/ja active Pending
- 2001-08-08 HU HU0300727A patent/HUP0300727A3/hu unknown
- 2001-08-08 EP EP01958342A patent/EP1307582B1/en not_active Expired - Lifetime
- 2001-08-08 AT AT01958342T patent/ATE397087T1/de not_active IP Right Cessation
- 2001-08-08 CA CA002418936A patent/CA2418936A1/en not_active Abandoned
- 2001-08-08 AU AU2001280060A patent/AU2001280060A1/en not_active Abandoned
- 2001-08-08 PL PL01366000A patent/PL366000A1/pl unknown
- 2001-08-08 IL IL15432401A patent/IL154324A0/xx unknown
- 2001-08-08 EP EP08156995A patent/EP2163642A1/en not_active Withdrawn
- 2001-08-08 CZ CZ2003444A patent/CZ2003444A3/cs unknown
- 2001-08-08 WO PCT/IL2001/000733 patent/WO2002012539A2/en not_active Ceased
- 2001-08-08 DE DE60134234T patent/DE60134234D1/de not_active Expired - Lifetime
-
2003
- 2003-02-20 ZA ZA200301386A patent/ZA200301386B/en unknown
- 2003-05-02 US US10/429,093 patent/US7767201B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US7767201B2 (en) | 2010-08-03 |
| EP1307582A4 (en) | 2004-09-22 |
| EP1307582A2 (en) | 2003-05-07 |
| ZA200301386B (en) | 2004-03-31 |
| EP1307582B1 (en) | 2008-05-28 |
| HUP0300727A3 (en) | 2005-12-28 |
| JP2004520009A (ja) | 2004-07-08 |
| DE60134234D1 (de) | 2008-07-10 |
| US20040151707A1 (en) | 2004-08-05 |
| AU2001280060A1 (en) | 2002-02-18 |
| IL154324A0 (en) | 2003-09-17 |
| HUP0300727A2 (hu) | 2003-10-28 |
| WO2002012539A2 (en) | 2002-02-14 |
| CA2418936A1 (en) | 2002-02-14 |
| ATE397087T1 (de) | 2008-06-15 |
| EP2163642A1 (en) | 2010-03-17 |
| WO2002012539A3 (en) | 2002-05-16 |
| CZ2003444A3 (cs) | 2003-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA03003238A (es) | Formulaciones dentifricas anhidro para el suministro de ingredientes incompatibles. | |
| WO2002019969A3 (en) | (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents | |
| WO2001032596A8 (en) | Phenoxy carboxylic acid compounds and compositions for delivering active agents | |
| WO2000040203A3 (en) | Polymeric delivery agents and delivery agent compounds | |
| WO2000007979A3 (en) | Compounds and compositions for delivering active agents | |
| IL193332A0 (en) | Isoflav-3-ene compounds, therapeutical composition containing them and their use for manufacturing medicaments | |
| HUP0203902A3 (en) | Substituted oxazolidinones, process for their preparation and pharmaceutical compositions containing them and their use | |
| IL231675A (en) | Concentrated protein compositions with reduced viscosity | |
| WO2001026693A3 (en) | Manufacture of polyglutamate-therapeutic agent conjugates | |
| IL161857A0 (en) | Pharmaceutical compositions of 5,7,14-triazatetracycloÄ10.3.1.0(2,11).0(4,9)Ü-hexadeca-2(11)3,5,7,9-pentaene | |
| AU2002223684A1 (en) | Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity | |
| ZA200206905B (en) | Azetidine derivatives, preparation thereof and pharmaceutical compositions containing same. | |
| ZA200405657B (en) | Formulation & dosage form for the controlled delivery of therapeutic agents. | |
| NZ524138A (en) | Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents | |
| WO2001005355A3 (en) | Formulations for il-11 | |
| WO2003045306A3 (en) | Phenoxy amine compounds and compositions for delivering active agents | |
| HUP0400832A3 (en) | New amidoalkyl-piperidine and amidoalkyl-piperazine derivatives, and pharmaceutical compositions containing such derivatives as active ingredients | |
| PL374325A1 (pl) | Bursztyniany 5,8,14-triazatetracyklo[10.3.1.0 2,11 .0 4,9]-heksadeka-2(11),3,5,7,9-pentaenu i ich środki farmaceutyczne | |
| MXPA01012478A (es) | Formulaciones farmaceuticas mejoradas. | |
| HUP0204202A3 (en) | Ibuprofen containing active agent preparation, process for its preparation and pharmaceutical compositions containing it | |
| WO2002015959A3 (en) | Compounds and compositions for delivering active agents | |
| AU2002309038A1 (en) | Compositions for transmucosal administration containing coenzyme Q as the active ingredient | |
| PL367179A1 (pl) | Preparaty 3,7-diazabicyklo[3.3.1] jako związki przeciwarytmiczne | |
| IL154324A0 (en) | Nucleic acid constructs, vascular cells transformed therewith, pharmaceutical compositions and methods utilizing same for inducing angiogenesis | |
| AP2004003045A0 (en) | Preparation compositions containing acid-unstable physiologically active compounds and process for producing the same. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DISC | Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications) |